1
These changes are thought to be intricately related to the cause, development, and severity of the disease. Researchers have demonstrated that inflammation around plaques destroys neighboring neurons. Plaques, which are composed of Amyloid-β Peptide (AβP), form as a result of its overproduction from its precursor protein (APP). A combination of genetic predisposition and environmental influence is believed to be responsible for the onset of the disease.
Many potential treatments for Alzheimer's disease are being investigated including the administration of drugs that could remove plaques, immunotherapy with Aβ amyloid antibodies, non-steroidal antiinflammatory drugs (NSAIDs) and statins. The protective effects of estrogen, antioxidants (Vitamins A, C and E), ginkgo biloba and omega-3 fatty acids (found mainly in fish such as tuna and salmon) are also being tested in trials. However, none of them appear to have proved optimal for treating AD.
The central problem in AD is the accumulation of AβP which weakens and kills the nerve cells. Hence, inhibition of AβP production, by blocking gamma-secretase activity, is at present one of the most promising therapeutic strategies anticipated to slow the progression of Alzheimer's disease pathology. Thus, majority of the new drugs focus on gamma secretase that snips a major protein, Amyloid Precursor Protein (APP), in order to produce AβP. The gamma secretase has crucial roles in the body in addition to making AβP. It removes stubs of proteins left behind on the surface of nerve cells and is needed to make other proteins, like Notch, an essential protein for body's function, therefore complete blocking may be problematic. Ablation of the PS1 and PS2 genes, therefore, results in a phenotype indistinguishable from that caused by a Notch knockout and completely blocks production of AβP and NICD (Notch IntraCellular Domain) production.
2 Moreover, mutagenesis of the critical aspartates also blocks the function of human PS in Notch signalling. Therefore, inhibition of PS activity not only blocks Aβ production, but also interferes with NICD generation and the Notch pathway. Notch plays a pivotal role in the development of blood-forming organs and the immune system.
Semagacestat, a g-secretase inhibitor introduced by Eli Lilly, for example, worked like a sledgehammer to stop gamma secretase on its tracks and halt all of its functions impairing patient's ability to perform daily activities. Other experimental drugs may also affect the enzyme's other targets. Moreover, a dozen potential products designed to slow clumps of protein from forming in the brain, a condition linked to the disease since 1906, have failed in mid-to latestage testing since 2003. New research from the laboratory of Nobel Laureate Dr. Paul Greengard from Rockefeller University, New York, however, suggests that treatments with the anticancer drug Gleevec or its analogue could be the solution.
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Earlier research by Greengard's lab showed that Gleevec successfully inhibited the ability of gamma secretase to form AβP without affecting the Notch pathway.
4 A recent study led by him has added a new twist to the mode of action of Gleevec for treating AD. They have shown that Gamma Secretase Activating Protein (GSAP) modulates g-secretase specifically to stimulate production of AβP in cell lines therefore its inhibition by Gleevec inhibited AβP generation (Fig. 1) . The researchers also looked at GSAP's action in a mouse model of Alzheimer's disease. They knocked down the gene that codes for GSAP using RNA interference, and found that levels of betaamyloid as well as plaque development decreased. Biochemical studies showed that Gleevec reduces beta-amyloid production by binding to GSAP and preventing its activation of gamma-secretase activity.
Hence, the approach taken by Greengard and his team is revolutionary. Their aim is not to deactivate the enzyme itself, but targeting the protein that guides the enzyme to snip APP and to produce AβP. Deactivating the newly discovered gamma secretase activating protein will not affect the other functions of gamma secretase and only inhibit the production of AβP in the brain. Unfortunately, the Gleevec molecule does not cross the blood-brain barrier, that prevents some substances in the blood from entering the brain. Greengard, however, believes that it will be possible to design drugs that target GSAP but do not have this limitation.
"Anti-amyloid therapeutic drugs represent a valid approach to treating Alzheimer's disease, but their inability to accumulate in the brain has limited their usefulness," says Greengard. Another problem with Gleevec is that it does not stay in the brain long enough and is pumped out before it can act upon the required proteins. However, according to several medical experts, these are highly promising discoveries in the field of Alzheimer's treatment and very soon, using Gleevec as the 'lead molecule', a chemical can be synthesized that reaches and stays in the brain and blocks the appearance of the AβP. 
